Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews

No studies found 4 · 50%GRADE not reported 2 · 25%Very low 2 · 25%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lack of efficacy withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low

Adverse event withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low

Serious adverse events · adults with chronic neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deaths · adults with chronic neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Hydromorphone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Hydromorphone showed no clear difference in average pain scores (0-100 VAS) compared with morphine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD 0.60 [-9.24, 10.44]
1 study · 56 participants
GRADE not reported

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
Sufentanil vs hydromorphone (Coda 1997): no statistically significant difference; no separate estimate reported
1 study
GRADE not reported